The US Food and Drug Administration (FDA) has granted PMA-Supplement approval for Flowonix Medical’s intrathecal infusion device, the Prometra II system.

Flowonix Medical intends to introduce the drug infusion device in the next few months.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Prometra II drug infusion device is small, self-contained and battery-powered, which helps to automatically dose drugs directly into the intrathecal space around the spine.

It features a flow-activated safety valve (FAV), which helps patients have magnetic resonance imaging (MRI) without the necessity of drug removal prior to the procedure.

West Virginia University School of Medicine clinical professor of Anesthesiology Timothy Deer said: "The proprietary flow-activated safety valve was designed to shut off drug flow to the patient in the event a high flow rate occurs during an MRI procedure.

See Also:

"The Prometra II drug infusion device is small, self-contained and battery-powered, which helps to automatically dose drugs directly into the intrathecal space around the spine."

"While the Flowonix Prometra infusion technology is already the most accurate and longest-lasting option for our patients, Prometra II increases safety and clinical convenience, should the patient require an MRI.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"This is an important advancement for the Prometra family of products and one that will be welcomed by physicians who treat chronic pain and cancer pain patients."

MRI is an imaging procedure that may be contraindicated for patients with implanted devices, while Prometra II system is labelled as MR-conditional and can safely undergo such scans, providing specific conditions are followed.

Flowonix Medical president Steve Adler said: "The new Prometra II drug infusion device is a major breakthrough for Flowonix, physicians, and patients, since it will improve the MR compatibility of the already state-of-the-art Prometra drug infusion device.

"The development and approval of the flow-activated valve demonstrates Flowonix’s commitment to innovation and safety."